News

Alterations in the compositions and metabolic functions of intestinal microbiota between AMD patients and healthy controls may help elucidate specific targets for AMD treatment.

The announcement resulted from the FDA’s request for manufacturing, administration, and patient monitoring information.

New data indicate that once-daily roflumilast foam in treating seborrheic dermatitis may improve the lives of those in the 5% or more of the global population with the skin disease.

The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.

An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.

Investigators found that dermatologist and convolutional neural network-cooperation led to improved lesion classification, indicating potential benefits of the human and machine approach for patients.

Data show older age, being female, having a high BMI, smoking, comorbidities, and previous hospitalization or ICU admission with COVID-19 were associated with an increased risk of developing Post-COVID-19 condition.

A single-center study reports no significant difference in global peripapillary RNFL thickness in eyes treated with intravitreal brolucizumab during a short-term follow-up period after injection.

Depression is linked with an increased incidence of multiple nonoverlapping physical conditions requiring hospital treatment, including endocrine, musculoskeletal, and vascular diseases.

Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.

New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

All countries in Africa now provide a three-dose infant hepatitis B vaccination beginning at age 6-8 weeks.

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our April 2023 month-in-review features data on the association between social determinants of health and vision loss, preferences for AMD monitoring, and the launch of a new multimedia series.

Clozapine treatment may offer the added benefit of improved sleep in patients with schizophrenia, according to a meta-analysis.

Older adults with comorbidities, including diabetes and chronic heart and lung disease, are at an increased risk of RSV hospitalization and death.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

An analysis of more than 4000 people from a university hospital in Japan details the impact of the COVID-19 pandemic on glycemic control and lipid profiles among people with diabetes.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

There were also 9 RT176 strains that carried the cfr(E)gene and one RT001 strain carried the cfr(C) gene. However, they were without a linezolid resistance.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.